Combined autophagy and proteasome inhibition
Top Cited Papers
- 19 May 2014
- journal article
- Published by Taylor & Francis in Autophagy
- Vol. 10 (8), 1380-1390
- https://doi.org/10.4161/auto.29264
Abstract
The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradati...Keywords
This publication has 43 references indexed in Scilit:
- Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiencyProceedings of the National Academy of Sciences, 2012
- Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma CellsPLOS ONE, 2012
- Principles and Current Strategies for Targeting Autophagy for Cancer TreatmentClinical Cancer Research, 2011
- Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagyMolecular Cancer Therapeutics, 2009
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaBlood, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPSNature, 2007
- Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphomaJournal of Clinical Investigation, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005